MRC1 and ovarian cancer: On the other hand, 1 of the 3 (33.3%) ovarian cancers and 1 of the 4 (25.0%) endometrial cancers that developed in carriers of MMR P/LP variants but retained the somatic heterozygosity of the germline-variant allele exhibited an MSI-H status (Figure 3C).